首页/数据集/Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer

Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer

NIAID Data Ecosystem2026-03-06 收录

结直肠癌靶向治疗

药物联合疗法评估

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2122780 数据链接链接失效反馈

官方服务：

资源简介：

In this study, the investigators assessed the effect of Cetuximab in combination with chemotherapy in the treatment of unresectable metastatic colorectal cancer.

应用场景：

创建时间：

2006-09-15

结直肠癌靶向治疗

老年肿瘤临床试验

OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC)

NIAID Data Ecosystem70

Design and Synthesis of a 2‑Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy

CDK8抑制剂

结直肠癌靶向治疗

CDK8 is a transcriptional cyclin-dependent kinase and considered as a potential target in colon cancer therapeutics. Here, a novel selective CDK8 inhibitor was identified against colon cancer in vivo.

Figshare60

DataSheet1_Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway.ZIP

结直肠癌靶向治疗

AKT/mTOR信号通路

Colorectal cancer (CRC) has become one of the top ten malignant tumors with a high incidence rate and mortality. Due to the lack of a good CRC screening program, most of the CRC patients are being tra

NIAID Data Ecosystem20

Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

生物标志物预测

结直肠癌靶向治疗

This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the treatment, the invest

NIAID Data Ecosystem60

Phase l and Phase ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

结直肠癌靶向治疗

临床剂量优化

Interventions: S-1 +oxaliplatin (SOX) + cetuximab Cetuximab: loding dose 400 mg/m2, 250 mg/m2/week L-OHP: 75-130 mg/m2 tri-weekly S-1: 80 mg/m2 (80-120 mg/day) Primary outcome(s): Phase I: Maximum Tol

NIAID Data Ecosystem30

Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer

资源简介：

相关数据集